SG/CALL/BRISTOL-MYERS SQUIBB/70/0.1/20.06.25

SG/CALL/BRISTOL-MYERS SQUIBB/70/0.1/20.06.25 Share Price

DE000SW7MH19

Market Closed - Boerse Frankfurt Warrants 01:15:04 15/06/2024 am IST
0.027 ^EUR	+17.39%

Current month	+19.23%
1 month	-34.04%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart BRISTOL-MYERS SQUIBB COMPANY

Chart SG/CALL/BRISTOL-MYERS SQUIBB/70/0.1/20.06.25

Latest news about BRISTOL-MYERS SQUIBB COMPANY

Bristol Myers: FDA approval for treatment	14/06	CF
Bristol-Myers Squibb's Augtyro Gets FDA Accelerated Approval for Treatment of Solid Tumors	14/06	MT
Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval	14/06	DJ
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors	14/06	BU

More news

Quotes 5-day view

Date	Price	Change
14/24/14	0.031	+34.78%
13/24/13	0.023	-23.33%
12/24/12	0.03	-6.25%
11/24/11	0.032	+14.29%
10/24/10	0.028	+3.70%

Real-time Boerse Frankfurt Warrants

Last update June 15, 2024 at 01:15 am IST

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	BRISTOL-MYERS SQUIBB COMPANY
Issuer	Société Générale
WKN	SW7MH1
ISIN	DE000SW7MH19
Date issued	12/03/2024
Strike	70 $
Maturity	20/06/2025 (369 Days)
Parity	10 : 1
Emission price	0.16 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	0.18 €
Lowest since issue	0.02 €
Spread	0.01 €
Spread %	27.78%

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

More about the company